Drug intelligence / Profile preview

ono-7914 + ono-4538

Development stage: Discontinued
Lead developer: Ono Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

ONO-7914 + ONO-4538 is an **experimental combination therapy** for advanced or metastatic solid tumors. ONO-7914's precise mechanism and class have not been disclosed publicly but it is being investigated in oncology. **ONO-4538** is the code name for **nivolumab**, a human IgG4 monoclonal antibody targeting the programmed cell death 1 receptor (**PD-1**), functioning as an immune checkpoint inhibitor to enhance antitumor immune response. The combination aims to determine safety, tolerability, and pharmacokinetics in patients with advanced cancers.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ono-7914 + ono-4538.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ono-7914 + ono-4538.

Explore the full profile